-- Grant up to $17.8 million will support study of treatment-shortening regimen in drug-sensitive tuberculosis (DS-TB)
-- Study expected to begin in 2022 evaluating safety and efficacy of novel 3-drug combination versus existing 4-drug standard of care

CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multidrug-resistant TB

Deltyba has been granted a marketing authorization for use as part of an appropriate combination regimen for MDR-TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.